超深度测序检测治疗前HIV-1逆转录酶抑制剂耐药 minority 变异对病毒学结局影响有限
该研究对50例HIV-1感染者基线血浆RNA和PBMC DNA进行单分子实时测序,比较病毒学成功组与失败组治疗前少数耐药变异(MDRV)的差异。结果显示,基于RNA或DNA检测的逆转录酶抑制剂耐药相关突变率在组间无显著差异,MDRV与病毒学结局无显著关联;但DNA测序检测MDRV比RNA更敏感,DNA超深度测序可能对评估病毒学应答有潜在临床价值。
要点
- 基线MDRV与病毒学结局无显著关联,无论基于RNA还是DNA分析。
- DNA超深度测序检测MDRV比RNA更敏感,可能更具临床相关性。
- 拉米夫定DNA分析中,病毒学失败组中/高水平耐药趋势更高,但无显著差异。
核心结论
- 超深度测序检测治疗前HIV-1逆转录酶抑制剂少数耐药变异与病毒学结局无显著关联。
- HIV-1 DNA超深度测序有助于检测治疗前耐药突变,可能影响病毒学应答,具有潜在临床相关性。
研究设计与样本
- 对50例HIV-1感染者基线血浆RNA和PBMC DNA进行单分子实时测序,并使用斯坦福HIV-1耐药数据库识别耐药相关突变。
- 将患者分为病毒学成功组和病毒学失败组,比较两组治疗前少数耐药变异及病毒学失败时的优势变异。
主要发现
- 基于RNA或DNA分析,逆转录酶抑制剂耐药相关突变率在组内和组间均无显著差异。
- 除拉米夫定DNA分析外,两组间对特定药物的耐药水平无显著差异;拉米夫定DNA分析中病毒学失败组中/高水平耐药趋势更高。
- RNA少数耐药变异与DNA少数耐药变异对应,但M100I和Y188H例外。
- DNA测序检测少数耐药变异比RNA更敏感。
临床怎么用
- 超深度测序检测治疗前少数耐药变异对病毒学结局的预测价值有限,不应单独作为调整治疗的依据。
- DNA超深度测序可能更敏感地发现治疗前耐药突变,可考虑用于评估潜在病毒学应答。
局限性
- 样本量较小(50例),可能影响统计效能。
- minority 变异与病毒学结局的关联需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Ultra-deep sequencing (UDS) is a powerful tool for exploring the impact on virological outcome of minority variants with low frequencies, some even <1% of the virus population. Here, we compared HIV-1 minority variants at baseline, through plasma RNA and PBMC DNA analyses, and the dominant variants at the virological failure (VF) point, to evaluate the impact of minority drug-resistant variants (MDRVs) on virological outcomes. METHODS: Single-molecule real-time sequencing (SMRTS) was performed on baseline RNA and DNA. The Stanford HIV-1 drug resistance database was used for the identification and evaluation of drug resistance-associated mutations (DRAMs). RESULTS: We classified 50 patients into virological success (VS) and VF groups. We found that the rates of reverse transcriptase inhibitor (RTI) DRAMs determined by SMRTS did not differ significantly within or between groups, whether based on RNA or DNA analyses. There was no significant difference in the level of resistance to specific drugs between groups, in either DNA or RNA analyses, except for the DNA-based analysis of lamivudine, for which there was a trend towards a higher prevalence of intermediate/high-level resistance in the VF group. The RNA MDRVs corresponded to DNA MDRVs, except for M100I and Y188H. Sequencing from DNA appeared to be more sensitive than from RNA to detect MDRVs. CONCLUSIONS: Detection of pretreatment minority HIV-1 RTI-resistant variants by UDS showed that MDRVs at baseline were not significantly associated with virological outcome. However, HIV-1 DNA sequencing by UDS was useful for detecting pretreatment drug resistance mutations in patients, potentially affecting virological responses, suggesting a potential clinical relevance for ultra-deep DNA sequencing.
引用
- Su B, Zheng X, Liu Y, et al. Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes. J Antimicrob Chemother. 2019. PMID: 30668734. doi:10.1093/jac/dky561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。